Verona Pharma PLC Holding(s) in Company (9441F)
May 23 2017 - 2:44AM
UK Regulatory
TIDMVRP
RNS Number : 9441F
Verona Pharma PLC
23 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
------------------------------------------------------------- -----------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
---------------------------------------------------------------- --------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
---------------------------------------------------------------- --------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
---------------------------------------------------------------- --------------------------------
An event changing the breakdown of voting rights
---------------------------------------------------------------- --------------------------------
Other (please X
specify):
Change to
notifiable
interest following
share issue.
--------------------------------------------------------- ----- --------------------------------
3. Full name of person(s) Abingworth LLP
subject to the Abingworth Bioventures VI
notification obligation: LP
(iii)
----------------------------------------------------------- -------------------------------------
4. Full name of shareholder(s) State Street (Nominees) Limited
(if different from 3.):(iv) (as nominee for Abingworth
Bioventures V LP)
----------------------------------------------------------- -------------------------------------
5. Date of the transaction 19 May 2017
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- -------------------------------------
6. Date on which issuer 22 May 2017
notified:
----------------------------------------------------------- -------------------------------------
7. Threshold(s) that is/are Downward crossing of the 7%,
crossed or threshold
reached: (vi, vii)
----------------------------------------------------------- -------------------------------------
8. Notified details: Abingworth LLP
----------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- -------------------------------- --------------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
-------------- --------------- --------------- ---------------------- --------------------- ---------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
-------------- ----------- ----------- ---------------------- --------- ---------- ------------ -------------
Verona Pharma
plc 3,510,553 3,510,553 3,510,553 0 3,510,553 0 3.36%
GB00B06GSH43
5p Ords
--------------- --------------- ------------ ------------------- ---------- -------------- -----------
Verona Pharma
plc
US9250501064
ADSs 3,705,000 3,705,000 3,705,000 0 3,705,000 0 3.54%
-------------- --------------- --------------- ------------ ------------------- ---------- -------------- -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ ------------- --------------------------------------- ----------------------- -----------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
---------------- ------------- ------------- ------------------------ ----------------------- -------------------------
Nominal Delta
---------------- ------------- ------------- ------------------------ ----------------------- -------------- ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------------
7,215,553 6.90%
-------------------------------------------------- ------------------------------------------------------------------------
8. Notified details: Abingworth Bioventures VI LP
-----------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
-----------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- -------------------------------------------- ---------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
-------------- ----------------- ------------------------- ------------ ----------------------- ------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
-------------- ----------- ----------- -------- ------------ ------------ --------- ------------ ----------
Verona Pharma
plc 3,510,553 3,510,553 3,510,553 3,510,553 0 3.36% 0
GB00B06GSH43
5p Ords
--------------- ------------------------- ------------ -------------- --------- ------------ ----------
Verona Pharma
plc
US9250501064
ADSs 3,750,000 3,750,000 3,705,000 3,705,000 0 3.54 0
-------------- --------------- ------------------------- ------------ -------------- --------- ------------ ----------
B: Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ --------------- --------------------------------------- ------------------------- --------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
---------------- --------------- ------------- ------------------------ ------------------------- ----------------------
Nominal Delta
---------------- --------------- ------------- ------------------------ ------------------------- ---------- ----------
Total (A+B+C)
-----------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------------------------------ ---------------------------------------------------
7,215,553 6.90%
------------------------------------------------------------------------ ---------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-----------------------------------------------------------------------------------------------------------------------------
Abingworth Bioventures VI LP (which holds 7,215,553
shares in the company (6.90%)) is managed by Abingworth
LLP.
Proxy Voting:
-----------------------------------------------------------------------------------------------------------------------------
10. Name of the proxy holder:
---------------------------------------------------------------------------------------- -----------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
---------------------------------------------------------------------------------------- -----------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
---------------------------------------------------------------------------------------- -----------------------------------
13. Additional information:
------------------------------------------------------------------------ ---------------------------------------------------
14. Contact name: John Heard
------------------------------------------------------------------------ ---------------------------------------------------
15. Contact telephone number: 020 7534 1500
------------------------------------------------------------------------ ---------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUGCAUPMUMW
(END) Dow Jones Newswires
May 23, 2017 03:44 ET (07:44 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
